In-house and online event | Registrations are essential
*Please note this is a hybrid seminar with registration options for in-house attendance and livestream.
This seminar will include presentations from two research studies focussing on anal cancer. Professor Joel Palefsky will present the ANal Cancer/HSIL Outcomes Research study (ANCHOR) results and their implications. ANCHOR was a randomised study designed to answer whether treatment of anal cancer precursors prevents anal cancer among persons living with HIV. Dr Mary Poynten will talk about the Study of the Prevention of Anal Cancer, a study of the natural history of anal HPV and associated disease in HIV-negative and HIV-positive gay and bisexual men provides data that can inform the development of anal cancer screening programs in Australia.
Professor Joel Palefsky
Joel Palefsky is an internationally recognised expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world’s first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the chair of the ANCHOR Study. He is founder and past president of the International Anal Neoplasia Society.
Dr Mary Poynten
Mary Poynten is a clinical epidemiologist who has worked at the Kirby Institute for 19 years. She was project leader of the Study of the Prevention of Anal Cancer and is lead investigator on two studies of anal cancer screening in high-risk populations
Opinions expressed in the Kirby Institute Seminar Series are solely those of the speaker and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.